US Stem Cell Inc (USRM) Ord USD0.001
U.S. Stem Cell, Inc., formerly Bioheart, Inc., is a biotechnology company. The Company is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. Its AdipoCell is a cell therapy with multiple possible treatment applications using autologous adipose cells. Its business includes the development of cell therapy products, as well as physician and patient-based regenerative medicine/cell therapy training services, and the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. It operates through divisions, including US Stem Cell Training, Vetbiologics and US Stem Cell Clinic.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.